|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Menlo Park, California-based company said it had net income of 2 cents per share. The biotechnology company posted revenue of $3 million in the period. In the final minutes of trading on Monday, the ...
CORRECTION to Article Published on July 10, 2017 issued by RDInvesting.com we are correcting this article to state "Cara reported that all the patients who received 5 mg dose of CR845 for 8 weeks ...
NEW YORK, NY / ACCESSWIRE / July 10, 2017 / Cara Therapeutics saw its shares close down nearly 10% on Friday after its phase 2b trial for its new investigational pain relief drug CR845 failed to meet its ...
TAIPEI, Taiwan, June 1, 2017 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPex: 4174), announced today an agreement with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) to acquire TH-3424, ...
NEW YORK, NY / ACCESSWIRE / May 23, 2017 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) stock ...
NEW YORK, May 18, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...